An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-73763989 in Adult Participants
Latest Information Update: 23 Dec 2022
At a glance
- Drugs JNJ 73763989 (Primary)
- Indications Hepatitis B; Hepatitis D
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 20 Dec 2022 Status changed from recruiting to completed.
- 27 Sep 2022 Planned End Date changed from 15 Sep 2022 to 15 Nov 2022.
- 27 Sep 2022 Planned primary completion date changed from 15 Sep 2022 to 15 Nov 2022.